Sciety is happy to invest in Capitainer once again, together with the network Sciety Venture Partners. The company offers an entirely new way of providing blood samples, which could simplify the process for patients, especially those in need of regular monitoring. We see significant potential for the company to make a substantial impact on its market, with considerable benefits for both patients and healthcare providers.

Apart from strengthening the company financially, we are convinced that the investment from We Venture Capital will result in synergies which also will strengthen the company strategically in its work to position itself as a leading player in the self-sampling market.

We are delighted to once again invest in Neogap and thus be able to contribute to important advances in cancer treatment. The company has a unique approach that is based on the realisation that each cancer is unique and differs between different patients and tumors. By using proprietary algorithms for machine learning and patented technology to train the patient’s own T-cells to attack the cancer cells, the company develops a completely individualised treatment. The company’s first indication, colorectal cancer, is the second most common cause of cancer death, so there is a great medical need here.